1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Sangamo Therapeutics Enter into Agreement with Genentech for Neurodegenerative Diseases

08 Aug 2024
Admin
News Article

Sangamo Therapeutics Enter into Agreement with Genentech for Neurodegenerative Diseases

Overview

Sangamo Therapeutics a leader in genomic medicine, has announced a licensing agreement with Genentech, part of the Roche Group, to develop intravenously administered genomic treatments for specific neurodegenerative disorders.

Conditions of Agreement

As per the agreement, Sangamo will handle the technology transfer and some preclinical activities, while Genentech will oversee clinical development, regulatory processes, manufacturing, and global commercialisation.
Genentech is expected to pay Sangamo $50 million in upfront license fees and milestone payments in the near term.
Sangamo could earn up to $1.9 billion in development and commercial milestones for multiple potential products under this agreement, along with tiered royalties on net sales, subject to specified reductions.
This agreement with Genentech to advance potential treatments for devastating neurodegenerative disorders hopes to be the start of several capsid collaborations with other partners.

Exclusive License by Sangamo

Sangamo has provided Genentech with an exclusive license to its proprietary zinc finger repressors targeting the tau gene, which plays a critical role in Alzheimer’s disease and other tauopathies, as well as a second, undisclosed neurology target. Additionally, Sangamo has agreed to license its neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, to Genentech.
This capsid has shown significant blood-brain barrier penetration and brain transduction in nonhuman primates.
The newly discovered STAC-BBB AAV capsid, delivered intravenously, promises to overcome long-standing obstacles in delivering therapies to the central nervous system.

Combined Expertise for Innovative Treatments

Combined expertise in neurological research uniquely positions to explore innovative treatments, including gene therapy, for neurodegenerative diseases.
This commitment to scientific innovation through partnerships with companies like Sangamo drives towards significant advancements in early diagnosis and treatment.

Aout Sangamo

Sangamo remains engaged in discussions with other potential partners regarding its STAC-BBB capsid delivery platform, epigenetic regulation capabilities, and additional assets, including treatments for Fabry disease.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!